

Original Article

Dexmedetomidine as an Adjunctive Sedative in Patients Undergoing Endoscopic Submucosal Dissection: A Systematic Review and Meta-Analysis

Hazem Abosheishaa^{1*}, Abdalfatah Abdalfatah², Abdelmalek Abdelghany², Arshia Sethi¹, Abdellatif Ismail³, Doha Mohamed², Moataz Aboeldahb⁴, Omar Abdelhalim¹, Islam Mohamed⁵, Ahmed Y. Azzam⁶, Muhammed Amir Essibayi⁷, David J. Altschul⁷, Mahmoud Nassar⁸, Mohammad Bilal⁹

1- Department of Internal Medicine, Icahn School of Medicine at Mount Sinai / NYC Health + Hospitals Queens, NY, USA.

2- Faculty of Medicine, October 6 University, Giza, Egypt.

3- University of Maryland Medical Center Midtown Campus, Baltimore, MD, USA.

4- Mayo Clinic Gastroenterology and Hepatology, Rochester, MN, USA

5- Department of Gastroenterology, University of Missouri, Columbia, MO, USA

6- Montefiore-Einstein Cerebrovascular Research Lab, Albert Einstein College of Medicine, Bronx, NY, USA.

7- Department of Neurological Surgery, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY, USA.

8- Department of Medicine, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, NY USA.

9- Division of Gastroenterology and Hepatology, Minneapolis Veterans Affairs Medical Center, Minneapolis, MN, USA.

ARTICLE INFO

Article history:

Received 11 Nov. 2024

Received in revised form 26 Nov. 2024

Accepted 15 Dec. 2024

Keywords:

Endoscopic Submucosal Dissection

ESD

Dexmedetomidine

Precedex

Systematic Review

Meta-Analysis

ABSTRACT

Introduction: Endoscopic submucosal dissection (ESD) is a technique for removing dysplastic lesions in the gastrointestinal tract but carries risks like pain and perforation. Dexmedetomidine, an α_2 -receptor agonist, offers potential benefits as an adjunct sedative during ESD by providing anxiolysis and analgesia. This systematic review and meta-analysis assesses its efficacy and safety.

Methodology: We searched databases including Embase, Medline/PubMed, Scopus, and Web of Science up to April 21, 2024, following PRISMA guidelines. Eligible studies used dexmedetomidine with other sedatives for ESD. We analyzed outcomes such as en-bloc and complete resection rates, sedation duration, and adverse events, using RevMan for meta-analysis with a random-effects model.

Results: The initial search retrieved 216 studies and after screening, eight studies were included in the final analysis. Dexmedetomidine showed no significant difference in en-bloc or complete resection rates compared to controls. Sedation and procedure times were similar between the two groups as well. Dexmedetomidine significantly reduced restlessness (OR 0.15, 95% CI:0.07 to 0.29) and increased bradycardia (OR 7.15, 95% CI 3.17 to 16.11) compared to controls. Upon subgroup analysis, Dexmedetomidine plus Propofol, and Dexmedetomidine plus Midazolam, revealed the same findings regarding restlessness and bradycardia compared to controls which confirmed the adjunctive effects of Dexmedetomidine.

Conclusion: Dexmedetomidine as an adjunctive sedative appears safe and effective in ESD, reducing restlessness without significant adverse events. The risk of bradycardia is increased, which may be reflective of reduced physiological stress. Future studies should explore optimal dosing and compare Dexmedetomidine with other sedatives in diverse populations.

1. Introduction

Endoscopic tumor resection is one of the most common modalities in GI tumor management. Endoscopic submucosal dissection (ESD) is considered superior to mucosal resection in view of offering complete resection with negative histological margins irrespective of the size of the original lesion [1]. Despite these overwhelming advantages, ESD is

associated with multiple postoperative complications including bleeding, postoperative perforation, and minor complications like abdominal pain, nausea, vomiting, and stricture which limits its use [2]. Post-operative abdominal pain is a debilitating complication associated with ESD which is severely underestimated and results in decreased patient satisfaction and longer hospital stays. Studies show the incidence of postoperative pain in 44.9–62.8% of patients, especially in the early

* **Corresponding author:** Hazem Abosheishaa, Internal Medicine Department, Icahn School of Medicine at Mount Sinai, NYC Health + Hospitals Queens, NY, USA. Email Address: hazemabosheishaa@gmail.com.

post-operative period necessitating the use of aggressive pain management [3, 4]. Dexmedetomidine is a new α_2 -receptor agonist that has anxiolytic, sedative, and analgesic properties which when used in combination with other anesthetics help lower their dose and also decrease postoperative opioid consumption and pain intensity [5, 6]. A study done by Chang et al., also shows a better cardiovascular profile of dexmedetomidine as compared to propofol [7]. In our study, we reviewed the possible benefits of dexmedetomidine as an adjunct sedative perioperatively in patients undergoing ESD for GI adenomas and early-stage neoplastic lesions. We evaluated its efficacy by assessing variables like en-bloc resection, Complete resection, sedation time, procedure time, patient restlessness, and other adverse events.

2. Methodology:

2.1. Search Strategy and Data Extraction:

A systematic search of relevant literature was conducted across multiple databases, including Embase, Scopus, Web of Science, Medline/PubMed, and Cochrane, from their inception to February 28, 2024. The search strategy utilized Boolean operators to combine terms related to the population, intervention, and outcomes of interest. The following search strategy was employed: ("endoscopic submucosal dissection" OR "ESD" OR "submucosal dissection") AND ("dexmedetomidine" OR "dexametomidine" OR "sedative") (Table 1). The search strategy aimed to identify studies investigating the use of dexmedetomidine as an adjunctive sedative in endoscopic submucosal dissection procedures. Our research adhered to the recommended guidelines for reporting systematic reviews and meta-analyses. The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) checklist and Cochrane criteria were followed to ensure transparency and completeness in reporting [8, 9].

Two independent reviewers screened titles, abstracts, and full-text articles for inclusion based on predefined eligibility criteria. Any disagreements were resolved through discussion or consultation with a third reviewer. Data extraction was conducted independently by two co-authors using a standardized data extraction form, with discrepancies resolved through consensus. Extracted data included study characteristics, patient demographics, details of the intervention and comparator, and outcomes of interest.

2.2. Inclusion Criteria and Study Outcomes:

Studies eligible for inclusion in this meta-analysis were those focusing on patients who had gastrointestinal adenomas and early-stage neoplastic lesions eligible for endoscopic submucosal dissection (ESD) treatment. The intervention of interest was the use of dexmedetomidine as an adjunctive medication in combination with other sedatives in submucosal endoscopic dissection. There was no specific comparator for this review. The primary outcome of interest was the en-bloc resection (successful removal of the entirety of a tumor without violation of its capsule). Secondary outcomes included Complete resection (excision of all affected tissue, including the tumor and a healthy surrounding tissue) sedative time (duration during which a sedative medication exerts its effects on a patient in minutes) procedure time (total duration taken to complete the surgery), restlessness (inability to remain still), and different adverse events (eg. Hypoxia, Brady cardia, Hypotension, Perforation and bleeding). Included study designs were randomized controlled trials (RCTs) and observational studies if applicable. Studies not written in English or with inadequate translation, Systematic reviews, Meta-analyses, Case reports, editorials, letters, or conference abstracts without full-text availability, animal studies, or studies conducted on non-human subjects were excluded.

2.3. Risk of Bias Assessment:

The risk of bias and methodological quality of the included studies was assessed independently by two authors. The Cochrane risk-of-bias tool version 2, (ROB 2) was employed for RCTs. For observational studies, we used the Newcastle-Ottawa Scale, any discrepancies were resolved through discussion or consultation with a third reviewer [10].

2.4. Statistical Analysis:

A meta-analysis was conducted using Review Manager 5.4 (Cochrane

Collaboration, Copenhagen, The Nordic Cochrane Centre). Given the anticipated heterogeneity in study designs and populations, a random-effects model was utilized. Summary measures were expressed as pooled odds ratios (OR) with corresponding 95% confidence intervals (CI) for proportional variables and mean differences with corresponding 95% CIs for continuous variables. Statistical significance was set at a p -value < 0.05 . Heterogeneity was assessed using the I² statistic, with an I² value of $\geq 50\%$ indicating significant heterogeneity defined by the Cochrane Handbook for systematic reviews [11].

3. Results

3.1. Search results:

The initial search retrieved 216 studies, 105 duplicates removed automatically with covidence, and 7 duplicates removed manually. The remaining 104 underwent title and abstract screening, and 25 full texts were assessed for inclusion. Eight studies [3,18-20,24-25,28-29] were included in our final analysis (Figure 1).

3.2. Study and patient characteristics:

A total of 836 patients were included in our meta-analysis. Of the 836 patients, 412 (49.2%) were assigned to the Dexmedetomidine group, whereas 424 (50.7%) were assigned to the placebo group. The included eight studies' characteristics are displayed in (Table 2).

3.3. Quality of included studies:

Quality assessment of included studies was assessed using (the Cochrane RoB 2 tool) for Randomized clinical trials. Four studies had a total low risk of bias, and one study had a moderate risk of bias. Another three Cohort studies were assessed using the Newcastle–Ottawa Scale with a low risk of bias (Table 3).

3.4. Meta-analysis outcomes:

3.4.1. En-bloc resection

The data from 7 studies were analyzed for En-bloc resection, the odds ratio was 1.45 with a 95% CI of 0.47 to 4.41 which revealed no significant difference between the two groups ($p=0.52$) at random effect as shown in (Figure 2).

3.4.2. Complete resection:

Three studies reported a complete resection rate, and the odds ratio was 0.62 with a 95% CI of 0.21 to 1.80 which revealed no significant difference between the two groups ($p=0.38$) as shown in (Figure 3).

3.4.3. Sedation time:

The pooled results from four studies reporting on sedation time revealed that there was no significant difference between the two groups, as shown in Figure 4 (Mean Difference (MD): 7.36, 95% CI: -1.42 to 16.15; I² 0%; P=0.10).

3.4.4. Procedure Time:

Five studies reporting on procedure time revealed that there was no significant difference between the two groups as shown in Table. 3 (MD: 3.21, 95% CI: -6.32-12.74; I² 0%; P=0.51).

3.4.5. Restlessness:

Four studies reported a restlessness rate, the odds ratio was 0.15 with a 95% CI of 0.07 to 0.29 which revealed a significant difference between the two groups ($p<0.00001$), as shown in (Table. 4).

3.4.6. Bradycardia:

Seven studies reported the bradycardia rate. The odds ratio was 7.15 with a 95% CI of 3.17 to 16.11 which revealed a significant difference between the two groups ($p<0.00001$) as shown in (Table. 4).

3.4.7. Hypoxia:

Four studies reported the Hypoxia rate. The odds ratio was 0.95 with a 95% CI of 0.38 to 2.36 which revealed no significant difference between the two groups ($p=0.91$) as shown in (Table 4).




Figure 1: Flowchart of Study Selection Process for Systematic Review.

Table 1: Search strategy:

Database	Search Terms	Search Field	Search Results
Medline	("endoscopic submucosal dissection" OR "ESD" OR "endoscopic dissection") AND ("dexmedetomidine" OR "Dexmedetomidine Hydrochloride" OR "Precedex" OR "MPV-1440" OR "MPV 1440" OR "MPV1440").	All Field	17
Cochrane	("endoscopic submucosal dissection" OR "ESD" OR "endoscopic dissection") AND ("dexmedetomidine" OR "Dexmedetomidine Hydrochloride" OR "MPV-1440" OR "MPV 1440" OR "MPV1440")	All Text	27
WOS	((ALL= (((endoscopic submucosal dissection OR ESD OR endoscopic dissection)))) AND ALL= (((Dexmedetomidine OR Dexmedetomidine Hydrochloride OR MPV-1440 OR MPV 1440 OR MPV1440)))).	All Fields	32
SCOPUS	("endoscopic submucosal dissection" OR "ESD" OR "endoscopic dissection") AND ("dexmedetomidine" OR "Dexmedetomidine Hydrochloride" OR "MPV-1440" OR "MPV 1440" OR "MPV1440").	Title, Abstract, Keywords	59
EMBASE	Embase: ("endoscopic submucosal dissection" OR "ESD" OR "endoscopic dissection") AND ("dexmedetomidine" OR "Dexmedetomidine Hydrochloride" OR "MPV-1440" OR "MPV 1440" OR "MPV1440").	All Field	81

ESD: Endoscopic Submucosal Dissection; WOS: Web of Science

Table 2: baseline characteristics of included studies

Author	Country	Study design	Age means (SD)		Intervention(t/control)	Procedure location	Size of lesion mean (SD)	
			Cases	Control			Cases	Control
Ashikari 2021 [24]	Japan	RCT	21.25 (8.29)	22.97 (12.78)	propofol plus DEX; propofol alone.	Superficial esophageal cancers	68.86 (30.99)	8 (24.24)
Iwagami 2023 [27]	Japan	Retrospective	NA	NA	MDZ and pethidine hydrochloride + DEX; MDZ and pethidine hydrochloride	Colorectal lesions	64.4(38.2)	85 (55)
Kim 2015 [14]	Korea	RCT	62.8 (8.5)	65.1 (10.2)	DEX- remifentanyl; propofol-remifentanyl	Esophagus	62.9 (12.3)	10 (34.5)
Kinugasa 2018 [28]	Japan	RCT	22.4 (4.3)	22.5 (2.77)	DEX + Pethidine; Pethidine	Colorectal	67.9 (33.8)	21 (52%)
Lee 2015 [18]	Korea	RCT	23.79 (2.70)	24.32 (2.07)	DEX with on-demand MDZ; MDZ alone	Gastric Tumor	15	22.5
Luo 2023 [3]	China	RCT	57 (7)	55.8 (7.5)	DEX bolus + maintenance intraop; Normal saline	Stomach - gastric	3.4 (1.2)	2.8 (1.3)
Nonaka 2016 [19]	Japan	Retrospective	66.3 (7.7)	68.4 (8.5)	Combination of propofol and DEX; Benzodiazepines	Esophagus	40.1 (12)	40.8 (15.2)
Yoshio 2019 [17]	Japan	Prospective confirmatory single arm	67.7 (5.7)	N/A	Bolus MDZ and pethidine + DEX infusion; MDZ and pethidine boluses	Esophagus	17.3 (8.5)	N/A

SD: Standard Deviation; RCT: Randomized Controlled Trial; DEX: Dexmedetomidine; MDZ: Midazolam; NA: Not Available; intraop: Intraoperative.

Table 3: Risk of bias assessment for included studies.

Author name, year	Study design	Tool used	Overall, ROB
Ashikari, 2021 [24]	RCT	Cochrane RoB 2	Low
Iwagami, 2023 [27]	Cohort	Newcastle–Ottawa Scale	Low
Kim, 2015 [14]	RCT	Cochrane RoB 2	Low
Kinugasa, 2018 [28]	RCT	Cochrane RoB 2	Low
Lee, 2015 [18]	RCT	Cochrane RoB 2	Low
Luo, 2023 [3]	RCT	Cochrane RoB 2	Moderate
Nonaka, 2016 [19]	Cohort	Newcastle–Ottawa Scale	Low
Yoshio, 2019 [17]	Cohort	Newcastle–Ottawa Scale	Moderate

RCT: Randomized Controlled Trial; ROB: Risk of Bias.

Table 4. Outcomes summary

Subgroup	Outcome	Odds Ratio / Mean Difference (95% CI)	P-value
General	Procedure time	3.21 (-6.32 to 12.74)	0.51
	Restlessness	0.15 (0.07 to 0.29)	<0.00001
	Bradycardia	7.15 (3.17 to 16.11)	<0.00001
	Hypoxia	0.95 (0.38 to 2.36)	0.91
	Hypotension	2.73 (0.79 to 9.43)	0.11
	Perforation	0.51 (0.05 to 5.44)	0.58
	Bleeding	0.41 (0.12 to 1.39)	0.15
Dexmedetomidine plus Propofol	En-bloc resection	3.09 (0.12 to 78.70)	0.49
	Complete resection	0.72 (0.23 to 2.24)	0.57
	Procedure time	-4.05 (-27.57 to 19.47)	0.74
	Restlessness	0.14 (0.05 to 0.45)	0.0009
	Bradycardia	10.04 (2.92 to 34.54)	0.0003
	Hypoxia	0.28 (0.11 to 0.71)	0.007
	Hypotension	3.83 (1.00 to 14.69)	0.05
Dexmedetomidine plus Midazolam	En-bloc resection	1.80 (0.50 to 6.51)	0.37
	Restlessness	0.15 (0.06 to 0.35)	<0.0001
	Bradycardia	14.97 (2.44 to 91.68)	0.003
	Hypoxia	0.80 (0.33 to 1.94)	0.62
	Bleeding	0.42 (0.11 to 1.60)	0.20
	Perforation	0.24 (0.01 to 4.13)	0.32

3.4.8. Hypotension:

Seven studies reported the Hypotension rate. The odds ratio was 2.73 with a 95% CI of 0.79 to 9.43 which revealed no significant difference between the two groups ($p=0.11$) as shown in (Table 4).

3.4.9. Perforation:

Five studies reported the perforation rate. The odds ratio was 0.51 with a 95% CI of 0.05 to 5.44 which revealed no significant difference between the two groups ($p=0.58$) as shown in (Table 4).

3.4.10. Bleeding:

Three studies reported the Bleeding rate, the odds ratio was 0.41 with a 95% CI of 0.12 to 1.39 which revealed no significant difference between the two groups ($p=0.15$) as shown in (Table 4).

3.5. Subgroup Analysis Outcomes:

3.5.1. Dexmedetomidine plus Propofol

3.5.1.1. En-bloc resection:

Two studies reported en-bloc resection rate for Dexmedetomidine in combination with propofol, the odds ratio was 3.09 with a 95% CI of 0.12 to 78.70 which revealed no significant difference between the two groups ($p=0.49$) as shown in (Table 4).

3.5.1.2. Complete resection:

Two studies reported a complete resection rate for Dexmedetomidine in combination with propofol, the odds ratio was 0.72 with a 95% CI of .23 to 2.24 which revealed no significant difference between the two groups ($p=0.57$) as shown in (Table 4).

3.5.1.3. Procedure Time:

Two studies reporting on procedure time for Dexmedetomidine in combination with propofol revealed that there was no significant difference between the two groups as shown in Table. 3 (MD: -4.05, 95% CI: -27.57-19.47; $I^2=63%$; $P=0.74$).

3.5.1.4. Restlessness:

Two studies reported Restlessness for Dexmedetomidine in combination with propofol, the odds ratio was 0.14 with a 95% CI of 0.05 to 0.45 which revealed a significant difference between the two groups ($p=0.0009$) as shown in (Table 4).

3.5.1.5. Bradycardia:

Two studies reported Bradycardia for Dexmedetomidine in combination with propofol, the odds ratio was 10.04 with a 95% CI of 2.92 to 34.54 which revealed a significant difference between the two groups ($p=0.0003$) as shown in (Table 4).

3.5.1.6. Hypoxemia:

Two studies reported hypoxemia for Dexmedetomidine in combination with propofol, the odds ratio was 0.28 with a 95% CI of 0.11 to 0.71 which revealed a significant difference between the two groups ($p=0.007$) as shown in (Table 4).

3.5.1.7. Hypotension:

Two studies reported Hypotension for Dexmedetomidine in combination with propofol, the odds ratio was 3.83 with a 95% CI of 1.00 to 14.69 which revealed a significant difference between the two groups ($p=0.05$) as shown in (Table 4).

3.5.2. Dexmedetomidine plus Midazolam

3.5.2.1. En-bloc resection:

Two studies reported en-bloc resection for Dexmedetomidine in combination with Midazolam, the odds ratio was 1.80 with a 95% CI of 0.50 to 6.51 which revealed no significant difference between the two groups ($p=0.37$) as shown in (Table 4).

3.5.2.2. Restlessness:

Two studies reported Restlessness for Dexmedetomidine in combination with Midazolam, the odds ratio was 0.15 with a 95% CI of 0.06 to 0.35 which revealed a significant difference between the two groups ($p < 0.0001$) as shown in (Table 4).

3.5.2.3. Bradycardia:

Two studies reported Bradycardia for Dexmedetomidine in combination with Midazolam, the odds ratio was 14.97 with a 95% CI of 2.44 to 91.68 which revealed a significant difference between the two groups ($p=0.003$) as shown in (Table 4).

3.5.2.4. Hypoxia:

Two studies reported Hypoxia for Dexmedetomidine in combination with Midazolam, the odds ratio was 0.80 with a 95% CI of 0.33 to 1.94 which revealed no significant difference between the two groups ($p=0.62$) as shown in (Table 4).

3.5.2.5. Bleeding:

Two studies reported Bleeding for Dexmedetomidine in combination with Midazolam, the odds ratio was 0.42 with a 95% CI of 0.11 to 1.60 which revealed no significant difference between the two groups ($p=0.20$) as shown in (Table 4).

3.5.2.6. Perforation:

Two studies reported Perforation for Dexmedetomidine in combination with Midazolam, the odds ratio was 0.24 with a 95% CI of 0.01 to 4.13 which revealed no significant difference between the two groups ($p=0.32$) as shown in (Table 4).

4. Discussion

Although the debilitating pain associated with ESD warrants aggressive pain management, physicians are hesitant due to the possibility of masking the pain of perforation. This not only causes patient discomfort but also increases the burden on healthcare by prolonging discharge time [2, 4]. A study done by Seiichiro et al. shows an increased incidence of metachronous gastric cancer in patients who underwent curative ESD of early gastric cancer [12]. These warrant further endoscopic surveillance and possible repeat ESD. However, poorly managed post-operative pain increases apprehension in patients for further endoscopic procedures. As previously described, a few studies have been done describing the incidence of postoperative pain after ESD but there is no consensus on the management of the said pain. Studies done by Lee and Kim recommend a single dose of dexamethasone or postoperative local bupivacaine and triamcinolone [13, 14].

In our study, we found a significant reduction in restlessness and bradycardia associated with dexmedetomidine highlighting its potential as an effective sedative agent for endoscopic procedures. A study that investigated the effect of local anesthesia in ESD procedures showed that local anesthesia decreased the incidence of bradycardia (OR = 0.16, 95% CI = 0.03, 0.95) [15]. We also observed a statistically significant decrease in tachycardia which could indicate less anxiety and pain thus providing a more comfortable sedative experience for the patients. These properties could be attributed to its selective alpha 2 adrenergic agonist and sympatholytic properties [15].

The non-significant difference found in en bloc resection rates between dexmedetomidine, and the comparator groups alleviated concerns regarding the influence of the sedation regimen on the technical aspects of the procedure [16].

The subgroup analysis also revealed better outcomes particularly in terms of reduced restlessness and bradycardia, with Dexmedetomidine in combination with Midazolam compared to other combinations. The anxiolytic and amnesic properties of Midazolam, coupled with the sedative and analgesic effects of Dexmedetomidine, may offer superior patient comfort and procedural tolerance. Additionally, considering the favorable safety profile of Midazolam in terms of respiratory depression compared to Propofol, this combination presents a compelling option for optimizing sedation strategies in endoscopic settings [17].




Figure 2: Forest Plot illustrating the Odds Ratios of Dexmedetomidine to control for En-bloc resection rates




Figure 3: Forest Plot illustrating the Odds Ratios of Dexmedetomidine to Control for complete resection rates




Figure 4: Forest Plot illustrating the Odds Ratios of Dexmedetomidine to Control for sedation time

Our review suggests that dexmedetomidine is an effective sedative agent for ESD. Lee et al. [18] on the other hand, compared the outcomes of sedation using dexmedetomidine infusion plus on-demand midazolam versus sedation using midazolam infusion plus on-demand midazolam. They concluded that the sedation effect of dexmedetomidine with midazolam was superior to the sedation effect with midazolam alone. Furthermore, four studies reported sedation time as an outcome, while five studies reported procedure time as an outcome, (Table 4). The pooled results from these studies showed no statistically significant difference in sedation or procedure time between the dexmedetomidine and the control group. Despite the significant reduction in intraoperative restlessness in the dexmedetomidine group in our review, as mentioned above, this did not translate into a shorter sedation or procedure time (Table 4).

Nonaka et al. [19] reported a significantly shorter procedure time in the combination group (dexmedetomidine and propofol) compared to the benzodiazepine group; nevertheless, this finding was lost after pooling with other studies in the analysis, as shown in (Table 4).

In terms of safety, our findings support the use of dexmedetomidine as an adjunctive agent in procedural sedation for ESD procedures, consistent with previous studies [20, 21]. As noted by Candiotti et al. [20], the Dexmedetomidine group demonstrated a higher incidence of bradycardia. However, there was no statistically significant increase in the occurrence of other adverse events such as hypoxia, hypotension,

bleeding, or perforation. Additionally, Dexmedetomidine's cardiovascular and hemodynamic effects are well-known and are attributed to its strong alpha 2-adrenergic agonist effect and include bradycardia, hypotension, and hypoxia [20-23]. Kim et al. evaluated risk factors for dexmedetomidine-associated bradycardia during spinal anesthesia [23] and found that a long tourniquet time and low baseline heart rate were associated with an increased incidence of bradycardia during procedures under spinal anesthesia. Notably, Alshikaria et al. [24] reported that no serious adverse events were observed in patients in the dexmedetomidine group who experienced bradycardia and that their clinical outcomes were not altered due to it, which is also consistent with previous literature [25, 26].

The use of Dexmedetomidine as an adjunctive sedative has shown promising results in our meta-analysis, yet this type of intervention needs further exploration. The included studies in this review have already explored the combination of Dexmedetomidine with the two main sedatives, propofol and midazolam. The results are extraordinary in terms of restlessness and bradycardia incidence, the latter being a good sign of less stress and discomfort during the procedure. Less movements (restlessness) during the ESD procedure leads to more convenient and accurate procedures from the operator. So, this therapy should be explored more to reach the best results possible for the patient.

More exploration means more multicenter randomized controlled trials and observational studies comparing this type of adjunctive therapy with

other adjunctive sedatives and even other types of pain management methods, like local anesthesia in the region of intervention, to test this intervention's safety and efficacy to standardize its use during ESD procedures in the near future.

Limitations: To our knowledge, this is the first meta-analysis to assess the safety and efficacy of Dexmedetomidine as an adjunctive sedative after ESD. Additionally, we performed subgroup analysis according to each general therapy. Most included articles (6 out of 8) did not conduct a head-to-head comparison between dexmedetomidine and other agents. Also, the limited number of published clinical trials and the number of patients included in certain subgroups make our evidence and conclusions limited on some outcomes. All of our eight included trials were conducted in eastern Asia, including 5 in Japan, two in Korea, and one in China. Thus, the generalizability of this study results to other regions with different ethnicities and medical environments may be affected. A standardized dosage of dexmedetomidine as an adjuvant sedative has not yet been established, resulting in a wide variety of dexmedetomidine regimens.

5. Conclusion

In conclusion, our meta-analysis supports the safe use of dexmedetomidine as an adjunctive sedative in ESD procedures. Dexmedetomidine, when combined with other sedatives, appears to reduce restlessness without increasing the risk of hypoxia, hypotension, bleeding, or perforation. The increased risk of bradycardia noted with dexmedetomidine can be perceived as less physiological stress and tachycardia during procedures. However, our findings are limited by the lack of direct comparisons with other sedatives and the predominantly Eastern Asian study populations. Further research, including multicenter trials, is needed to establish optimal dosing regimens and evaluate dexmedetomidine's efficacy compared to other sedatives and pain management methods in diverse patient populations.

Conflicts of Interest:

None

Ethical Approval:

None

Funding Source:

The project described was supported by the National Center for Advancing Translational Sciences (NCATS), National Institutes of Health, through CTSA award number: UM1TR004400. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.

Acknowledgements:

None

Institutional Review Board (IRB) Approval:

None

LLM Statement:

None

Authors Contribution Statement:

H.A., A.A., A.A., A.S., A.I., D.M., M.A., O.A., I.M., A.Y.A., M.N., and M.B. equally contributed to the conception, design, data acquisition, analysis, and interpretation of this research. All authors were involved in drafting the manuscript and revising it critically for important intellectual content. They have also given final approval of the version to be published and agree to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part

of the work are appropriately investigated and resolved.

Data Availability Statement:

All data generated or analyzed during this study are included in this published article. The data are publicly available and have been cited appropriately within the text of the document.

References

1. Isomoto H, Shikuwa S, Yamaguchi N, Fukuda E, Ikeda K, Nishiyama H, Ohnita K, Mizuta Y, Shiozawa J, Kohno S. Endoscopic submucosal dissection for early gastric cancer: a large-scale feasibility study. *Gut*. 2009; 331 [PMID: 19001058 <https://doi.org/10.1136/gut.2008.165381>]
2. Nishizawa T, Yahagi N. Endoscopic mucosal resection and endoscopic submucosal dissection: technique and new directions. *Curr Opin Gastroenterol*. 2017; 315 [PMID: 28704212 <https://doi.org/10.1097/MOG.0000000000000388>]
3. Luo X, An LX, Chen PS, Chang XL, Li Y. Efficacy of dexmedetomidine on postoperative pain in patients undergoing gastric and esophageal endoscopic submucosal dissection: a study protocol for a randomized controlled prospective trial. *Trials*. 2022; 491 [PMID: 35698203 <https://doi.org/10.1186/s13063-022-06432-4>]
4. Kim JW, Jang JY, Park YM, Shim JJ, Chang YW. Clinicopathological characteristics of patients with pain after endoscopic submucosal dissection for gastric epithelial neoplasm. *Surg Endosc*. 2019; 794 [PMID: 30014330 <https://doi.org/10.1007/s00464-018-6345-3>]
5. Ramsay MA, Luteran DL. Dexmedetomidine as a total intravenous anesthetic agent. *Anesthesiology*. 2004; 787 [PMID: 15329604 <https://doi.org/10.1097/0000542-200409000-00028>]
6. Liu Y, Liang F, Liu X, Shao X, Jiang N, Gan X. Dexmedetomidine Reduces Perioperative Opioid Consumption and Postoperative Pain Intensity in Neurosurgery: A Meta-analysis. *J Neurosurg Anesthesiol*. 2018; 146 [PMID: 2879737 <https://doi.org/10.1097/ANA.0000000000000403>]
7. Chang ET, Certal V, Song SA, Zaghi S, Carrasco-Llatas M, Torre C, Capasso R, Camacho M. Dexmedetomidine versus propofol during drug-induced sleep endoscopy and sedation: a systematic review. *Sleep Breath*. 2017; 727 [PMID: 28130737 <https://doi.org/10.1007/s11325-017-1465-x>]
8. Moher D, Liberati A, Tetzlaff J, Altman DG, Group P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *Int J Surg*. 2010; 336 [PMID: 20171303 <https://doi.org/10.1016/j.ijvsu.2010.02.007>]
9. Cumpston M, Li T, Page MJ, Chandler J, Welch VA, Higgins JP, Thomas J. Updated guidance for trusted systematic reviews: a new edition of the Cochrane Handbook for Systematic Reviews of Interventions. *Cochrane Database Syst Rev*. 2019; ED000142 [PMID: 31643080 <https://doi.org/10.1002/14651858.ED000142>]
10. Sterne JAC, Savovic J, Page MJ, Elbers RG, Blencowe NS, Boutron I, Cates CJ, Cheng HY, Corbett MS, Eldridge SM, Emberson JR, Hernan MA, Hopewell S, Hrobjartsson A, Junqueira DR, Juni P, Kirkham JJ, Lasserson T, Li T, McAleenan A, Reeves BC, Shepperd S, Shrier I, Stewart LA, Tilling K, White IR, Whiting PF, Higgins JPT. RoB 2: a revised tool for assessing risk of bias in randomised trials. *BMJ*. 2019; 14898 [PMID: 31462531 <https://doi.org/10.1136/bmj.14898>]
11. Deeks JJ, Bossuyt PM, Leeflang MM, Takwoingi Y (editors). *Cochrane Handbook for Systematic Reviews of Diagnostic Test Accuracy*. Version 2.0 (updated July 2023). Cochrane, 2023. Available from <https://training.cochrane.org/handbook-diagnostic-test-accuracy/current>

12. Abe S, Oda I, Suzuki H, Nonaka S, Yoshinaga S, Nakajima T, Sekiguchi M, Mori G, Taniguchi H, Sekine S, Katai H, Saito Y. Long-term surveillance and treatment outcomes of metachronous gastric cancer occurring after curative endoscopic submucosal dissection. *Endoscopy*. 2015: 1113 [PMID: 26165734 <https://doi.org/10.1055/s-0034-1392484>]
13. Lee HW, Lee H, Chung H, Park JC, Shin SK, Lee SK, Lee YC, Hong JH, Kim DW. The efficacy of single-dose postoperative intravenous dexamethasone for pain relief after endoscopic submucosal dissection for gastric neoplasm. *Surg Endosc*. 2014: 2334 [PMID: 24570015 <https://doi.org/10.1007/s00464-014-3463-4>]
14. Kim B, Lee H, Chung H, Park JC, Shin SK, Lee SK, Lee YC. The efficacy of topical bupivacaine and triamcinolone acetonide injection in the relief of pain after endoscopic submucosal dissection for gastric neoplasia: a randomized double-blind, placebo-controlled trial. *Surg Endosc*. 2015: 714 [PMID: 25060683 <https://doi.org/10.1007/s00464-014-3730-4>]
15. Afonso J, Reis F. Dexmedetomidine: current role in anesthesia and intensive care. *Rev Bras Anesthesiol*. 2012: 118 [PMID: 22248773 [https://doi.org/10.1016/S0034-7094\(12\)70110-1](https://doi.org/10.1016/S0034-7094(12)70110-1)]
16. Dumoulin FL, Hildenbrand R. Endoscopic resection techniques for colorectal neoplasia: Current developments. *World J Gastroenterol*. 2019: 300 [PMID: 30686899 <https://doi.org/10.3748/wjg.v25.i3.300>]
17. Yoshio T, Ishiyama A, Tsuchida T, Yoshimizu S, Horiuchi Y, Omae M, Hirasawa T, Yamamoto Y, Sano H, Yokota M, Fujisaki J. Efficacy of novel sedation using the combination of dexmedetomidine and midazolam during endoscopic submucosal dissection for esophageal squamous cell carcinoma. *Esophagus*. 2019: 285 [PMID: 30937573 <https://doi.org/10.1007/s10388-019-00666-z>]
18. Lee SP, Sung IK, Kim JH, Lee SY, Park HS, Shim CS, Hwang HK, Kim TY, Shim SG. Comparison of dexmedetomidine with on-demand midazolam versus midazolam alone for procedural sedation during endoscopic submucosal dissection of gastric tumor. *J Dig Dis*. 2015: 377 [PMID: 25944073 <https://doi.org/10.1111/1751-2980.12254>]
19. Nonaka T, Inamori M, Miyashita T, Harada S, Inoh Y, Kanoshima K, Matsuura M, Higurashi T, Ohkubo H, Iida H, Endo H, Kusakabe A, Maeda S, Gotoh T, Nakajima A. Feasibility of deep sedation with a combination of propofol and dexmedetomidine hydrochloride for esophageal endoscopic submucosal dissection. *Dig Endosc*. 2016: 145 [PMID: 26476104 <https://doi.org/10.1111/den.12559>]
20. Candiotti KA, Bergese SD, Bokesch PM, Feldman MA, Wisemandle W, Bekker AY, Group MACS. Monitored anesthesia care with dexmedetomidine: a prospective, randomized, double-blind, multicenter trial. *Anesth Analg*. 2010: 47 [PMID: 19713256 <https://doi.org/10.1213/ane.0b013e3181ae0856>]
21. Riker RR, Shehabi Y, Bokesch PM, Ceraso D, Wisemandle W, Koura F, Whitten P, Margolis BD, Byrne DW, Ely EW, Rocha MG, Group SS. Dexmedetomidine vs midazolam for sedation of critically ill patients: a randomized trial. *JAMA*. 2009: 489 [PMID: 19188334 <https://doi.org/10.1001/jama.2009.56>]
22. Bloor BC, Ward DS, Belleville JP, Maze M. Effects of intravenous dexmedetomidine in humans. II. Hemodynamic changes. *Anesthesiology*. 1992: 1134 [PMID: 1361311 <https://doi.org/10.1097/0000542-199212000-00014>]
23. Kim HJ, Ahn E. Risk factors for dexmedetomidine-associated bradycardia during spinal anesthesia: A retrospective study. *Medicine (Baltimore)*. 2022: e31306 [PMID: 36316937 <https://doi.org/10.1097/MD.00000000000031306>]
24. Ashikari K, Nonaka T, Higurashi T, Takatsu T, Yoshihara T, Misawa N, Arimoto J, Kanoshima K, Matsuura T, Fuyuki A, Ohkubo H, Chiba H, Nakajima A. Efficacy of sedation with dexmedetomidine plus propofol during esophageal endoscopic submucosal dissection. *J Gastroenterol Hepatol*. 2021: 1920 [PMID: 33506496 <https://doi.org/10.1111/jgh.15417>]
25. Mason KP, Robinson F, Fontaine P, Prescilla R. Dexmedetomidine offers an option for safe and effective sedation for nuclear medicine imaging in children. *Radiology*. 2013: 911 [PMID: 23449958 <https://doi.org/10.1148/radiol.13121232>]
26. Talon MD, Woodson LC, Sherwood ER, Aarsland A, McRae L, Benham T. Intranasal dexmedetomidine premedication is comparable with midazolam in burn children undergoing reconstructive surgery. *J Burn Care Res*. 2009: 599 [PMID: 19506498 <https://doi.org/10.1097/BCR.0b013e3181abff90>]
27. Iwagami H, Akamatsu T, Matsuyama K, Hanawa Y, Tonomura K, Chikugo E, Ogino S, Morimura H, Shimoyama M, Terashita T, Nakano S, Wakita M, Edagawa T, Konishi T, Matsumoto H, Nakatani Y, Urai S, Seta T, Uenoyama Y, Yamashita Y. Dexmedetomidine is safe and effective for reducing intraoperative pain in colorectal endoscopic submucosal dissection. *DEN Open*. 2023: e223 [PMID: 36992692 <https://doi.org/10.1002/deo2.223>]
28. Kinugasa H, Higashi R, Miyahara K, Moritou Y, Hirao K, Ogawa T, Kunihiro M, Nakagawa M. Dexmedetomidine for conscious sedation with colorectal endoscopic submucosal dissection: a prospective double-blind randomized controlled study. *Clinical and Translational Gastroenterology*. 2018: <https://doi.org/10.1038/s41424-018-0032-5>